AMP Survey on PGx Genotyping Recommendations

The Association for Molecular Pathology (AMP) Pharmacogenomics Working Group has launched a survey that is designed to understand the impact and evaluate the implementation of their series of recommendations on clinical PGx testing. The survey is designed to capture individual responses from molecular laboratory professionals currently performing, planning to perform, or who have decided not to perform clinical testing for PGx in their laboratories. One individual per laboratory should respond, ideally the laboratory director decision maker. This survey is NOT restricted to AMP members, so please feel free to share the survey link widely with colleagues who are working in this space. The survey will close on November 4, 2024.

PharmGKB and CPIC are represented in the AMP PGx Working Group, and the recommendations can be found on PharmGKB.